Starpharma Receives $7.1m R&D tax incentive refund
Biopharmaceutical company Starpharma (SPL) receives a $7.1 million research and development tax incentive refund
The tax offset...
Starpharma Registers VIRALEZE nasal spray in Indonesia
Starpharma (SPL) registers its nasal spray product VIRALEZE in Indonesia after gaining marketing authorisation
The company says...
Starpharma Spends September quarter progressing DEP technology
Starpharma (SPL) spent the September quarter progressing its DEP technology and signing a new research agreement
In...
Starpharma Expands research program with Genentech
Starpharma (SPL) expands its research agreement with Genentech for its drug delivery technology, DEP
The initial agreement was...
Starpharma Receives $7.7m R&D tax refund
Starpharma (SPL) receives a $7.7 million research and development tax incentive refund
The refund falls under the Australian...
Starpharma Continues VIRALEZE success in December quarter
Starpharma (SPL) releases its September quarterly report, with the period again highlighted by the continued success of...
During the September quarter, Starpharma (SPL) achieved several milestones with its SPL7013 COVID-19 nasal spray
Additionally, the pharmaceutical company made progress with its...
